<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051943</url>
  </required_header>
  <id_info>
    <org_study_id>ADAL-001-CNI</org_study_id>
    <nct_id>NCT05051943</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response</brief_title>
  <acronym>OPALE</acronym>
  <official_title>A Prospective Observational Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to describe the real-world profile of patients treated with&#xD;
      adalimumab FK in gastroenterology, dermatology or rheumatology in order to evaluate in this&#xD;
      population the predictive factors of therapeutic response (in particular nutritional status)&#xD;
      and generate hypothesis between nutritional status and therapeutic response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">September 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>12 months</time_frame>
    <description>The CGI provides an overall clinician-determined summary measure that takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function.</description>
  </primary_outcome>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Psoriasis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults patients with rhumatologic, gastrologic or dermatologic disease eligible to a&#xD;
        treatment with adalimumab&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients at least 18 years old who agree to participate in the study and do not object&#xD;
             to the use of their health data&#xD;
&#xD;
          -  A disorder treated with anti-TNF therapy&#xD;
&#xD;
          -  Whose physician made the decision to initiate adalimumab treatment prior to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients participating in an interventional therapeutic trial at the time of inclusion&#xD;
&#xD;
          -  Patients who are unwilling or unable to fulfil follow-up requirements (patients who&#xD;
             cannot be reached by phone or complete the self-administered questionnaire or not&#xD;
             fluent in French&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Peyrin-Biroulet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Brun, PhD</last_name>
    <phone>+ 33626427058</phone>
    <email>manuel.brun@fresenius-kabi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Graziella Pourcel, MD</last_name>
    <phone>+33 6 28 20 12 38</phone>
    <email>graziella.pourcel@fresenius-kabi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Peyrin-Biroulet, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

